Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short term Debt (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Short term Debt for 10 consecutive years, with $40.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt rose 2361.54% year-over-year to $40.0 million, compared with a TTM value of $40.0 million through Dec 2025, up 2361.54%, and an annual FY2025 reading of $40.0 million, changed N/A over the prior year.
  • Short term Debt was $40.0 million for Q4 2025 at Arrowhead Pharmaceuticals, roughly flat from $40.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $65.0 million in Q1 2025 and bottomed at $1.6 million in Q4 2024.